Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced from intestinal L cells of the gut and plays an important role in glucose-dependent insulin secretion, suppression of glucagon secretion, proliferation of pancreatic β-cells, and inhibition of food intake.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced from intestinal L cells of the gut and plays an important role in glucose-dependent insulin secretion, suppression of glucagon secretion, proliferation of pancreatic β-cells, and inhibition of food intake. 1 The short half-life of GLP-1 (t1/2 < 2 minutes) resulted from degradation by dipeptidyl peptidase IV (DPP-IV), however, has stymied the application of GLP-1 for the treatment of insulin-resistant type 2 diabetes.
2 Exendin-4, which is derived from saliva of a lizard Gila monster with ~53% sequence homology with GLP-1, has Gly in position 2 rather than Ala, as is the case in GLP-1. Thus, exendin-4 is resistant to the cleavage by DPP-IV and has a half-life of approximately 30 minutes after intravenous administration and 2 -3 hours after subcutaneous administration in humans. 3, 4 Previous research has been focused on the development of long-acting GLP-1 mimetics or DPP-IV inhibitors. A number of studies were reported on DPP-IV-resistant GLP-1 analogs with chemical modification 5, 6 or amino acid substitution, [7] [8] [9] [10] [11] [12] in which the latter largely relied upon substitutions of amino acid in the N-terminal region in GLP-1 to evade the proteolytic degradation by DPP-IV. In addition, efforts to prolong the half-life of GLP-1 by attaching macromolecules such as albumin or immunoglobulin heavy chains (IgG-Fc), which are widely found in serum, have been sought. For example, albumin fusion to GLP-1 was shown to activate GLP-1 receptor-dependent signaling pathways in baby hamster kidney cells. 13 The fusion of mouse IgG-Fc to human GLP-1 (GLP-1/IgG-Fc) increased the half-life of GLP-1 in mouse. 14 In this study we sought to elucidate whether the N-terminal extension of GLP-1 by a single amino acid, Ala or Gly, evades the degradation by DPP-IV using 7-amino-4-methylcoumarin (AMC)-conjugated tripeptide (Ala-His-Ala-AMC or Gly-HisAla-AMC). We further examined whether the N-terminal modified GLP-1/IgG-Fc fusion proteins could induce the expression of insulin receptor substrate-2 (IRS-2) in rat pancreatic β cells.
Many previous attempts to synthesize DPP-IV-resistant GLP-1 analogs have been focused on mutations of amino acids in the GLP-1 sequence. We constructed GLP-1/IgG-Fc fusion constructs with the N-terminal extension of GLP-1 by a single amino acid, Ala or Gly, in the pSGHV0 vector. 6×His tag followed by an enterokinase recognition sequence, AspAsp-Asp-Asp-Lys, were localized prior to the N-terminal end of GLP-1. The recombinant GLP-1/IgG-Fc fusion protein transiently expressed in CHO-K1 cells were secreted into medium, suggesting that the protein is folded properly. The recombinant GLP-1/IgG-Fc fusion protein was successfully purified using a 5-mL HisTrap column on FPLC (see concentration, suggesting that the fusion protein bound to the nickel resion with a high affinity. The fusion protein appeared on the SDS gel with a molecular weight of 58 kDa. Following buffer exchange, the enterokinase recognition sequence was cleaved off by enterokinase at 25 o C (see Fig. 1B ). Enterokinase cleaves the C-terminal side of the recognition sequence allowing complete removal of affinity tag sequences. Recombinant GLP-1/IgG-Fc fusion protein upon treatment of enterokinase appeared on the SDS gel as a 33 kDa band. The enterokinase enzyme was removed by protein A affinity column chromatography.
Previously high-performance liquid chromatography and mass spectrometry have been used for the identification of cleaved GLP-1 fragments upon DPP-IV treatment.
2, 15 In this study, we utilized the fluorescence change of AMC-conjugated peptides as a measure to examine if the N-terminal extension of GLP-1 by a single amino acid confers resistance to degradation by DPP-IV. The enzyme DPP-IV cleaves the N-terminal dipeptide of substrates, especially after amino acid Pro or Ala. 16 Native His-Ala-AMC and N-terminal extended Ala-HisAla-AMC and Gly-His-Ala-AMC were synthesized, respectively. It is expected that there would be no change of fluorescence if either of the tripeptides is resistant to DPP-IV. AMC itself showed its maximal emission at 440 nm upon excitation at 350 nm (see Fig. 2A ). The fluorescence emission from AMC-conjugated peptides was blue-shifted compared to AMC. Upon treatment of DPP-IV for 1 hour at 37 o C, the fluorescence emission from His-Ala-AMC was restored to the normal spectrum of AMC (see Fig. 2B ), suggesting that the peptide bond between His-Ala and AMC was cleaved off by DPP-IV. However, the treatment of DPP-IV had no effect on the fluorescence emission of Ala-His-Ala-AMC or Gly-HisAla-AMC (see Fig. 2C and 2D) , indicating that the peptide bond between the tripeptides and AMC is resistant to DPP-IV action.
Next, we examined the expression of IRS-2 in insulin-producing rat INS-1 cells to see the GLP-1/IgG-Fc fusion protein has retained its biological activity. The IRS-2 branch of insulin and insulin-like growth factor signaling pathways strongly promote β-cell growth and survival, which is essential for compensatory β cell function during physiological or metabolic stress. 17 GLP-1 induced 2-fold (2.0 ± 0.4) increase of IRS-2 protein expression (see Fig. 3 ). Upon treatment of wild-type GLP-1/IgG-Fc fusion protein, the expression of IRS-2 protein was increased 1.6-fold (1.6 ± 0.1), 20% lower than the induction of IRS-2 by GLP-1. The modified A-and G-GLP-1/IgG-Fc fusion protein both showed 1.2-fold (1.2 ± 0.1) and 1.5-fold (1.5 ± 0.2) increase of IRS-2 expression, respectively. Addition of Ala to the dipeptide led to 20% lower IRS-2 expression than the addition of Gly. Our data suggests that the N-terminal extension of GLP-1/IgG-Fc fusion protein by a single amino acid is functionally active. Ligand binding to the GLP-1 receptor occurs in two steps: the C-terminal region of GLP-1 initially binds to the receptor and a secondary contact occurs between the N-terminal region of GLP-1 and the transmembrane and extracellular loops of the GLP-1 receptor for receptor activation. 18, 19 Thus, it is believed that the decreased IRS-2 expression compared to native GLP-1 is in part due to structural hindrance in GLP-1 binding to the GLP-1 receptor by Fc fusion.
In conclusion, we demonstrated that the AMC-conjugated tripeptides were resistant to degradation by DPP-IV. Furthermore, both of the N-terminal extended GLP-1/IgG-Fc fusion proteins by a single amino acid, Ala or Gly, were functionally active by inducing the expression of IRS-2 in rat insulinoma INS-1 cells. Mechanisms of fusion protein binding to the GLP-1 receptor and signal generation need to be further elucidated in the future.
Experimental Section
Materials. Human glucagon cDNA was purchased from OriGene Technologies, Inc. (USA). Human GLP-1 was purchased from Sigma (USA). The pSGHV0 vector was kindly provided by Jong-Bok Yoon (Yonsei University, Seoul, Korea). 20 The pOPGFc plasmid containing human IgGγ-Fc was kindly provided by Young-Chul Sung (Pohang University of Science and Technology, Pohang, Korea). AMC-conjugated three peptides (His-Ala-AMC, Ala-His-Ala-AMC, and Gly-His-Ala-AMC) were synthesized at Peptron (Korea). Enterokinase was purchased from Invitrogen (USA). Monoclonal antibody to GLP-1 and polyclonal antibody to IRS-2 were purchased from Santa Cruz Biotechnology, Inc (USA). All other reagents, unless stated otherwise, were from Sigma (USA).
GLP-1/IgG-Fc fusion plasmid construction. The human IgGγ-hinge Fc sequence encoding 234 amino acids was amplified from the pOPGFc plasmid by polymerase chain reaction (PCR) with the following primers; the forward primer was 5'-GGATCCgctagcGAGCCCAAATC-3' (BamHI site underlined, linker sequence in small letters, and the N-terminal region of IgG-Fc in boldface type) and the reverse primer was 5'-GCGGCCGCTCATTTACCCGGAGA-3' (NotI site underlined and the C-terminal region of IgG-Fc in boldface type). The PCR product was sequenced and subcloned into the BamHI and NotI sites of the pSGHV0 vector, generating a construct of pSGHV0-Fc. Human GLP-1 was amplified from human glucagon cDNA by PCR with the following primers; the forward primer was 5'-GGATCCgacgatgacgataagCATG CTGAAGGGACC-3' (BamHI site underlined, enterokinase recognition sequence in small letters, and the N-terminal region of GLP-1 in boldface type), and the reverse primer was 5'-GA AATCTCGCTAGCTCCTCGGCC-3' (NheI site underlined and the C-terminal region of GLP-1 in boldface type). GLP-1 with an N-terminal Ala was amplified with the forward primer 5'-GGATCCgacgatgacgataaggctGCTCATGCTGAAGGGA CC-3' (BamHI site underlined, enterokinase recognition sequence in small letters, Ala double underlined, and the N-terminal region of GLP-1 in boldface type). GLP-1 with an N-terminal Gly was amplified with the forward primer 5'-GGATCCgacgatgacgataagGGACATGCTGAAGGGACC-3' (BamHI site underlined, enterokinase recognition sequence in small letters, Gly double underlined, and the N-terminal region of GLP-1 in boldface type). The PCR product digested with BamHI and NheI was subcloned into the pSGHV0-Fc vector. Accuracy of the fusion constructs in the expression vector was confirmed by DNA sequence analysis.
Expression of GLP-1/IgG-Fc fusion proteins. Chinese hamster ovary (CHO)-K1 cells were transfected with wild-type or modified GLP-1/IgG-Fc plasmid using polyethyleneimine according to the manufacturer's instructions. The 3, 6, 10-days conditioned medium were combined for protein purification.
Purification of GLP-1/IgG-Fc fusion proteins. Protein purification was carried out using AKTA Prime (GE Healthcare). 5-mL HisTrap FF column was equilibrated with buffer A (20 mM sodium phosphate, 0.5 M NaCl, pH 8.0). Following sample loading, the column was washed with buffer A and eluted with Buffer B (1 M imidazole) with 2 -50% gradient at 5 mL/min. After elution, proteins were concentrated using Vivaspin 20 (GE Healthcare). The fusion proteins were incubated with enterokinase (EKMax, Invitrogen) for 16 hours at 25 o C, and the enzyme was removed with EKAway affinity resin (Invitrogen). Cleaved fusion proteins were separated by Protein A Notes column chromatography (GE Healthcare), and neutralized with 1 M Tris․Cl, pH 8.0. Fusion protein in each fraction was separated by SDS-PAGE and stained by Coomassie staining solution and silver nitrate, respectively. The expression of fusion protein was also identified by immunoblotting with monoclonal antibody to GLP-1 followed by detection with ChemiDoc XRS (Bio-Rad). Each band was analyzed using Quantity One software (Bio-Rad).
Degradation by DPP-IV enzyme. AMC-conjugated peptides were synthesized, buffer exchanged with acetate buffer, and lyophilized. 100 µM of AMC-conjugated peptide in 500 µL of 50 mM Tris․HCl, 1 mM EDTA, pH 8.0 was incubated with DPP-IV for 1 hr at 37 Cells were harvested at 12,000 × g for 10 min and the supernatant was collected. 30 µg of cell lysates were separated by SDS-PAGE in a 10% separation gel and transferred onto nitrocellulose membrane. The expression of IRS-2 was identified by immunoblotting using polyclonal antibody to IRS-2.
